Rosuvastatin is a high-intensity statin that selectively inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis and upregulating LDL receptors.
Also known as: Crestor
No documented drug–drug interactions for this medicine.
Heavy alcohol use adds hepatotoxicity to rosuvastatin (transaminases) — labels discourage excessive intake in statin patients.
Moderate alcohol; transaminases as advised.
EMC-UK — Rosuvastatin (Crestor) SmPC 4.4 (hepatic, alcohol).
No documented disease interactions.
CONTRAINDICATED in pregnancy and breastfeeding. Risk of fetal malformations.
CONTRAINDICATED in all trimesters.
Do not use during breastfeeding.
Discontinue at least 3 months before conception.
DailyMed/FDA (NIH/NLM) — approved Rosuvastatin (Crestor) label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=325a5d0e-9a72-4015-9fcd-1655fb504cee
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Competitive and reversible inhibitor of HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. High-intensity statin.
Selectively inhibits HMG-CoA reductase, blocking conversion of HMG-CoA to mevalonate, a cholesterol precursor. Upregulates hepatic LDL receptors.
Oral bioavailability: ~20%. Food does not significantly affect absorption. Tmax: 3-5 hours.
Minimally metabolised by CYP2C9 (10%). Not a prodrug. Slightly inhibited by cimetidine. Low CYP-mediated interaction potential.
~19 hours. Elimination: ~90% faeces, ~10% urine. Long half-life allows once-daily dosing.
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
